Peroxisome proliferator‐activated receptor‐γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type‐2 diabetic rodents - Tureyen, Kudret; Kapadia, Ramya; Bowen, Kellie K.; Satriotomo, Irawan; Liang, Jin; Feinstein, Douglas L.; Vemuganti, Raghu (Journal of neurochemistry, 2007)
Keywords: Anilides - pharmacology; Animals; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cerebral Infarction - drug therapy; Cerebral Infarction - physiopathology; Cerebral Infarction - prevention & control; Chemotaxis, Leukocyte - drug effects; Chemotaxis, Leukocyte - physiology; Cytokines - genetics; Cytokines - metabolism; diabetes; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - physiopathology; Diabetes. Impaired glucose tolerance; Disease Models, Animal; Encephalitis - drug therapy; Encephalitis - metabolism; Encephalitis - physiopathology; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; gene expression; hypertension; Hypertension - genetics; Hypertension - physiopathology; Intercellular Adhesion Molecule-1 - drug effects; Intercellular Adhesion Molecule-1 - metabolism; Ischemic Attack, Transient - drug therapy; Ischemic Attack, Transient - physiopathology; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neuroprotective Agents - chemistry; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; PPAR gamma - agonists; PPAR gamma - antagonists & inhibitors; PPAR gamma - metabolism; PPAR‐γ; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; stroke; Superoxide Dismutase - drug effects; Superoxide Dismutase - genetics; Superoxide Dismutase - metabolism; Superoxide Dismutase-1; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins - drug effects; Suppressor of Cytokine Signaling Proteins - metabolism; thiazolidinedione; Thiazolidinediones - chemistry; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use; Endocrinopathy; Type 2 diabetes; Rat; Cardiovascular disease; Cerebral artery; Vascular disease; Ischemia; Transcription factor; Cerebrovascular disease; Peroxisome proliferator activated receptor; PPAR-γ; Hypertension; Nervous system diseases; Stroke; thiazolidinedione; Rodentia; Metabolic diseases; Inflammation; PPAR-γ receptor; Cerebral disorder; Vertebrata; Mammalia; Treatment; Mouse; Cell death; Central nervous system disease; Artery occlusion; diabetes; gene expression